MyVisionTest News Archive

Displaying news items tagged with Lucentis (More tags »)
SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last

Age-related macular degeneration
Jan 26, 2010
A novel platelet-derived growth factor currently being studied in clinical trials may boost the effect of anti-VEGF therapy and provide a benefit in patients with choroidal neovascularization secondary to age-related macular degeneration, according to a speaker at the at Retina 2010 meeting. A phase 1 trial of E10030 (Ophthotech), a PDGF-B...

Full Article


Radiation warning symbol
Jan 26, 2010
Interim analysis of a pilot study of combination anti-VEGF therapy and externally delivered radiation for the treatment of age-related macular degeneration has shown encouraging visual acuity and anatomical outcomes and no safety signals, according to a speaker at the Retina 2010 meeting. The IRay system (Oraya Therapeutics) delivers radiation...

Full Article


Branch retinal vein occlusion
Jan 26, 2010
Two large-scale randomized clinical trials demonstrate that anti-VEGF therapy significantly improves vision in patients with central or branch retinal vein occlusion, according to a speaker at the Retina 2010 meeting. In the CRUISE study, 130 patients who received a 0.5-mg dose of Lucentis (ranibizumab) in six monthly doses had a mean gain of 14...

Full Article


Intravitreal injection
Dec 21, 2009
The MARINA and ANCHOR clinical trials of Lucentis (ranibizumab) therapy for exudative age-related macular degeneration (AMD) followed a fixed dosage regimen and fixed duration of 2 years. Hence, the trials did not provide any information about the “when to stop” endpoint. Because anti-VEGF drugs are angiostatic - they inactivate rather than...

Full Article


VEGF molecule
Dec 17, 2009
Intravitreal Lucentis (ranibizumab) injections in patients with neovascular AMD results in decreased aqueous levels of VEGF and increased levels of platelet-derived growth factor (PDGF). Methods and results In this prospective clinical trial 28 eyes of patients with neovascular AMD were compared with 28 eyes of age-matched patients with...

Full Article


Retinal angiomatous proliferation
Nov 26, 2009
Treat and Extend is an effective dosing strategy for the treatment of patients with retinal angiomatous proliferation, according to a new study. Since the first suggestion of a non-monthly dosing regimen in the PrONTO study, many retinal specialists have moved toward dosing individualization, with maintenance therapy provided on an as-needed...

Full Article


Intravitreal injection
Nov 26, 2009
The vision of patients with persistent or reactivated choroidal neovascularization (CNV) that had been previously treated with photodynamic therapy (PDT) improve less than treatment-naive patients. Baseline assessments including best-corrected visual acuity, fluorescein angiography (FFA), and optical coherent tomography (OCT) were performed....

Full Article


Pigment epithelial detachment
Nov 26, 2009
Lucentis (ranibizumab) is ineffective in treating avascular pigment epithelial detachment (PED) secondary to age-related macular degeneration (AMD) over a 1 year follow-up period, according to a new study. A PED occurs when fluid enters the space between the retinal pigment epithelium (RPE) and choroid (Figure). A serous PED is when aqueous...

Full Article


Diabetes
Nov 24, 2009
Lucentis (ranibizumab) therapy produces a significantly better visual outcome than focal/grid laser in diabetic macular edema (DME), according to a new study. Diabetic retinopathy is the most prevalent cause of vision loss in working-age individuals in developed countries. Severe vision loss occurs because of tractional retinal detachments that...

Full Article


Intraocular pressure
Nov 20, 2009
Although temporary increases in intraocular pressure (IOP) are a known adverse effect of anti-VEGF medications for age-related macular degeneration (AMD), some patients develop persistent IOP — even without predisposing risk factors, according to research presented at the American Academy of Ophthalmology Annual Meeting. Whether this adverse...

Full Article


SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last
Most Popular
Less - past - More